trial · primary record
Keytruda
Post-Acute COVID-19 Syndrome
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 15 |
| Primary completion | 2028-01-01 |
| Primary endpoint | The primary outcome of this study is to determine the safety of a single dose of intravenous Pembrolizumab in participants with neurological post-acute sequalae of SARS-CoV-2 infection. |
| Registry ID | NCT07388550 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:18.981Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07388550
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.